This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Press Archive


ITM announces poster presentation outlining the ongoing phase III GEP-NET trial COMPETE at AACR Annual Meeting 2021

ITM will present an e-poster on the COMPETE phase III trial with lead candidate n.c.a. 177Lu-Edotreotide, a Targeted Radionuclide Therapy for GEP-NETs

ITM AG today announced that the company will present a poster describing the clinical trial design for its ongoing phase III trial COMPETE for their lead candidate, no-carrier-added Lutetium-177-Edotreotide (n.c.a. 177Lu-Edotreotide), a Targeted Radionuclide Therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting on April 10-15, 2021 and May 17-21, 2021.

The e-poster website will be launched on Saturday, April 10, 2021 at 8.30am ET and will remain available for viewing until Monday, June 21, 2021. Please see below for details on the poster abstract.

Session Category: Phase III Clinical Trials in Progress
Title: COMPETE Phase III Trial – Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide vs. Everolimus in Progressive GEP-NET
Authors: J.R. Strosberg, A. M. Avram, C. Mari Aparici, M. Wahba
Presenter: Mona Wahba, MD, Deputy CMO at ITM
Abstract Number: CT254

COMPETE is an international, prospective, randomized, controlled, open-label, multicenter phase III clinical trial to evaluate efficacy and safety of Targeted Radionuclide Therapy with n.c.a. 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).


                                                                                                                                  - End -

ITM Isotopen Technologien München
ITM, a radiopharmaceutical biotech company founded in 2004, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.
For more information please visit:


Contact ITM
Nicola Scharrer
Head of Marketing & Communications
Phone: +49 89 329 8986 151
Email: Nicola.Scharrer(at)

Media Requests ITM
Trophic Communications
Marie Weickert or Stephanie May
Phone: +49 151 598 624 18
Email: itm(at)


ITM Isotopen Technologien München AG
Executive Board: Steffen Schuster (CEO), Thomas Dürre (CFO)  -  Supervisory Board: Udo J Vetter (Chairman)  -  Registered Office: Garching/Munich
Commercial Register 154 944, District Court of Munich  -  Phone: +49 (0)89 329 8986 600  -  Fax: +49 (0)89 329 8986 650  -  Email: info(at)
VAT Number: DE813228901  -  Deutsche Bank München  -  IBAN: DE52680700300022816300  -  BIC: DEUTDE6FXXX